

SECURITIES AND EXCHANGE COMMISSION

FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2011-11-07** | Period of Report: **2011-11-07**

SEC Accession No. **0001191638-11-001400**

([HTML Version](#) on secdatabase.com)

FILER

GLAXOSMITHKLINE PLC

CIK: **1131399** | IRS No.: **000000000**

Type: **6-K** | Act: **34** | File No.: **001-15170** | Film No.: **111183574**

SIC: **2834** Pharmaceutical preparations

Mailing Address

980 GREAT WEST ROAD
BRENTFORD MIDDLESEX X0
TW8 9GS

Business Address

980 GREAT WEST ROAD
BRENTFORD MIDDLESEX X0
TW8 9GS
011442080475000

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending November 2011

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary shares of GlaxoSmithKline plc in respect of the under-mentioned persons, arising from the purchase of Ordinary shares on 4 November 2011 following the reinvestment of dividends, on shares held within an ISA at a price of 1388.995 pence per Ordinary share:

Mr A P Witty	24
Mr S M Bicknell	67
Mr E J Gray	7
Mr D S Redfern	7
Mrs V A Whyte	13

The Company and the above named persons were advised of this information on 7 November 2011.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Company Secretary

7 November 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: November 07, 2011

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc